These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer's Disease Spectrum with Amyloid PET Imaging. Lim HJ; Park JE; Kim BC; Choi SM; Song MK; Cho SH; Seo HJ; Kim J; Song HC; Choi KY; Lee JJ; Kim HW; Ha JM; Song WK; Park SG; Lee JS; Lee KH J Alzheimers Dis; 2020; 75(3):949-958. PubMed ID: 32390627 [TBL] [Abstract][Full Text] [Related]
46. Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Ossenkoppele R; Mattsson N; Teunissen CE; Barkhof F; Pijnenburg Y; Scheltens P; van der Flier WM; Rabinovici GD Neurobiol Aging; 2015 Aug; 36(8):2340-7. PubMed ID: 25990306 [TBL] [Abstract][Full Text] [Related]
47. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. Gisslén M; Krut J; Andreasson U; Blennow K; Cinque P; Brew BJ; Spudich S; Hagberg L; Rosengren L; Price RW; Zetterberg H BMC Neurol; 2009 Dec; 9():63. PubMed ID: 20028512 [TBL] [Abstract][Full Text] [Related]
48. PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers. Koychev I; Gunn RN; Firouzian A; Lawson J; Zamboni G; Ridha B; Sahakian BJ; Rowe JB; Thomas A; Rochester L; Ffytche D; Howard R; Zetterberg H; MacKay C; Lovestone S; J Alzheimers Dis; 2017; 60(1):283-293. PubMed ID: 28800330 [TBL] [Abstract][Full Text] [Related]
49. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677 [TBL] [Abstract][Full Text] [Related]
50. Chemokines in CSF of Alzheimer's disease patients. Corrêa JD; Starling D; Teixeira AL; Caramelli P; Silva TA Arq Neuropsiquiatr; 2011 Jun; 69(3):455-9. PubMed ID: 21755121 [TBL] [Abstract][Full Text] [Related]
51. TREM2-Deficient Microglia Attenuate Tau Spreading In Vivo. Lee-Gosselin A; Jury-Garfe N; You Y; Dabin L; Soni D; Dutta S; Rochet JC; Kim J; Oblak AL; Lasagna-Reeves CA Cells; 2023 Jun; 12(12):. PubMed ID: 37371067 [TBL] [Abstract][Full Text] [Related]
52. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid. Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913 [TBL] [Abstract][Full Text] [Related]
53. Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology. Lee SH; Meilandt WJ; Xie L; Gandham VD; Ngu H; Barck KH; Rezzonico MG; Imperio J; Lalehzadeh G; Huntley MA; Stark KL; Foreman O; Carano RAD; Friedman BA; Sheng M; Easton A; Bohlen CJ; Hansen DV Neuron; 2021 Apr; 109(8):1283-1301.e6. PubMed ID: 33675684 [TBL] [Abstract][Full Text] [Related]
54. In Vivo Microdialysis in Mice Captures Changes in Alzheimer's Disease Cerebrospinal Fluid Biomarkers Consistent with Developing Pathology. Bjorkli C; Louet C; Flo TH; Hemler M; Sandvig A; Sandvig I J Alzheimers Dis; 2021; 84(4):1781-1794. PubMed ID: 34719495 [TBL] [Abstract][Full Text] [Related]
55. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive. Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253 [TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease. Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543 [TBL] [Abstract][Full Text] [Related]
57. Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. Blennow K; Chen C; Cicognola C; Wildsmith KR; Manser PT; Bohorquez SMS; Zhang Z; Xie B; Peng J; Hansson O; Kvartsberg H; Portelius E; Zetterberg H; Lashley T; Brinkmalm G; Kerchner GA; Weimer RM; Ye K; Höglund K Brain; 2020 Feb; 143(2):650-660. PubMed ID: 31834365 [TBL] [Abstract][Full Text] [Related]
58. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease. Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737 [TBL] [Abstract][Full Text] [Related]
59. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease. Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478 [TBL] [Abstract][Full Text] [Related]
60. Alzheimer's Disease-Like Pathologies and Cognitive Impairments Induced by Formaldehyde in Non-Human Primates. Zhai R; Rizak J; Zheng N; He X; Li Z; Yin Y; Su T; He Y; He R; Ma Y; Yang M; Wang Z; Hu X Curr Alzheimer Res; 2018; 15(14):1304-1321. PubMed ID: 30182853 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]